Should healthcare be a public good, a market product, or some hybrid — and who pays?
Each issue breaks into the specific questions Congress actually fights over. Read each position, then head to the interactive version of this issue to mark which reflects your view and build a message to your representatives.
Universal coverage is a moral imperative, and there's no real replacement for the individual mandate the ACA lost. The ACA's individual mandate was effectively struck when its penalty was zeroed out in 2017, leaving millions uninsured without any replacement mechanism. Subsidies alone haven't closed that gap for everyone — 2026's expired enhanced premium tax credits show how fast marketplace enrollment can slide when the support isn't there.
Near-universal coverage is achievable through Medicaid expansion and generous marketplace subsidies, without necessarily needing a mandate. Marketplace enrollment hit roughly 24 million for 2026 even without a functioning mandate, showing subsidies can do real work on their own. But that same 2026 enrollment is now sliding as enhanced premium tax credits expired at the end of 2025 and average subsidized premiums roughly doubled — evidence subsidy generosity, not the mandate, is really what's driving coverage levels.
Forcing people to buy a product they don't want is government overreach; people should choose coverage that fits their needs and means. The individual mandate's practical death since 2017 hasn't caused the coverage collapse mandate supporters predicted. People should be able to choose bare-bones or high-deductible coverage that matches their actual health needs and budget, not a one-size-fits-all federal design.
A Medicare-for-All or robust public option would eliminate insurance-company profit from healthcare and improve bargaining power on drug prices. A public option removes the administrative overhead and profit margin that private insurers add on top of the cost of care. It would also give the government real bargaining leverage on drug and provider prices that fragmented private insurers don't have individually.
A public option competing with private insurance, rather than replacing it, gives consumers real choice while adding market pressure. It could extend coverage further without disrupting the existing employer-sponsored coverage most Americans currently have. A Medicaid buy-in for non-elderly adults has drawn more bipartisan support than a full public option, since it targets a specific coverage gap rather than restructuring the whole market.
A government-subsidized public option would crowd out private insurance and eventually collapse the market toward single-payer. That has real consequences for innovation, wait times, and quality that a purely private, competitive market doesn't face the same way. State-level public option experiments have had a mixed track record, which argues for caution before a federal version.
The U.S. pays 2-3x what other wealthy nations pay for the same drugs, and Medicare negotiation should be expanded, not left at its current scope. The IRA's Medicare drug price negotiation authority, finally enacted in 2022, initially covered only 10 high-cost drugs — a real start, but a small fraction of what Medicare spends on prescriptions overall. Expanding the number of negotiated drugs and letting private insurers use the negotiated prices would extend the savings well beyond Medicare's own enrollees.
Allowing Medicare to negotiate is a reasonable, scale-appropriate market intervention, and reference pricing plus faster generic approval can do more from there. The IRA's negotiation authority came in with prices significantly below prior market rates for the first batch of drugs covered. Reference pricing to international benchmarks and faster generic and biosimilar approval add competitive pressure without a blanket price-control regime.
Price controls reduce the pharmaceutical R&D investment that drives medical innovation, and high U.S. prices effectively subsidize drug development that benefits the whole world. Medicare's negotiated prices function as government-set price ceilings, which is functionally a price control even when it's called negotiation. Reducing the return on new-drug development risks fewer new therapies coming to market over the next decade, not just cheaper prices on existing ones.
Ten states still haven't expanded Medicaid under the ACA, leaving millions in a coverage gap too poor for marketplace subsidies and too well-off for traditional Medicaid. That gap exists purely because of a state political choice, not because federal funding isn't available to close it. Federal incentives, or a federal fallback in non-expansion states, would close a gap that's persisted for over a decade in some states.
ACA Medicaid expansion has demonstrably improved coverage, especially for rural and working-poor populations, and financial incentives can bring in the remaining holdout states. The 2021 American Rescue Plan added a temporary 5% enhanced federal match for newly expanding states, and two additional states expanded following that change. That shows a bigger financial incentive, not a mandate, is what's actually moved holdout states so far.
Medicaid expansion increases dependency, crowds out private coverage, and has shown mixed results on actual health outcomes. States should retain flexibility in program design rather than being pressured into a one-size-fits-all expansion. Holdout states have their own reasons — cost projections and program-design preferences — that a blanket federal mandate would override.
Insurance-market regulations — guaranteed issue, community rating, essential health benefits — are the core of the ACA and what made pre-existing condition protections real. Without those rules, insurers could once again charge more, or deny coverage outright, based on someone's health history. Rolling any of them back, even indirectly through expanded short-term plans, weakens protections that poll as broadly popular across party lines.
Balanced risk pools need some combination of mandates, subsidies, and regulation, and short-term plans that exempt young, healthy people undermine that balance for everyone else. When healthier people opt into cheaper, less-regulated short-term plans, the regulated marketplace pool gets sicker and more expensive on average. Reinsurance programs under ACA §1332 waivers have successfully stabilized several state markets without touching the core coverage guarantees.
ACA market regulations drive up premiums for healthy people in order to subsidize others, and deregulation would give people more choices at lower cost. Association health plans and expanded health savings accounts let individuals and small employers access coverage tailored to their actual needs rather than a mandated benefit package. State-level reinsurance programs have already shown that market-based stabilization tools can lower premiums without new federal mandates.